UBS Group’s Neurocrine Biosciences NBIX Stock Holding History

UBS Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-72,000	Closed	-$7.02M	–	10716
2022 Q2	$7.02M	Hold	72,000	–	–	﹤0.01%	2087
2022 Q1	$6.75M	Sell	72,000 -14,800	-17%	-$1.25M	﹤0.01%	2262
2021 Q4	$7.39M	Buy	86,800 +82,800	+2,070%	+$7.62M	﹤0.01%	2420
2021 Q3	$384K	Buy	+4,000	New	+$378K	﹤0.01%	4895
2015 Q1	–	Sell	-53,300	Closed	-$1.19M	–	9150
2014 Q4	$1.19M	Buy	+53,300	New	+$1.01M	﹤0.01%	3426

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's NBIX Position: Q1 2026 in Review

UBS Group increased its Neurocrine Biosciences (NBIX) stake by 24% in Q1 2026, buying an estimated $31.5M and bringing the position to 1,221,036 shares worth $161M. The position accounts for 0.02% of the portfolio, ranked #726.

UBS Group first reported a position in NBIX in Q4 2014 and has held it in 46 quarters since. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

UBS Group held 1,221,036 shares of Neurocrine Biosciences worth $161M as of Q1 2026.
UBS Group bought 237,508 Neurocrine Biosciences shares in Q1 2026, an estimated $31.5M.
Neurocrine Biosciences made up 0.02% of UBS Group's portfolio in Q1 2026, its #726 holding.
UBS Group first reported a position in Neurocrine Biosciences in Q4 2014 and has held it in 46 quarters since.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.